Regeneron Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Waste Management, Inc. trades at $235.99 (market cap $93.64B). The key difference: Waste Management, Inc. is the larger of the two by market cap, and Waste Management, Inc. pays the higher dividend (1.52%). Which is the better fit depends on your goals.
| REGN | WM | |
|---|---|---|
Market Cap | $70.79B | $93.64B |
Sector | Health | Industrials |
52-Week High | $812.27 | $246.51 |
52-Week Low | $545.46 | $196.77 |
Enterprise Value | $64.74B | $116.37B |
Dividend Yield | 0.56% | 1.52% |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
WM (Waste Management) trades at $233.18, down 2.56% on the day, but remains near its 52-week high of $248.13. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal steady revenue growth to $25.20 billion in 2025 and a robust 10.99% net income margin. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 results missed. Analyst sentiment is positive with a consensus buy rating and $263.57 price target, supported by a reliable dividend and strong cash flow from operations of $6.04 billion.
Outlook: WM's dominant market position, pricing power, and renewable energy initiatives support long-term growth, but high debt levels and competitive pressures pose risks. The stock offers value for income and growth investors, with potential upside to analyst targets if execution remains solid amid economic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →